|
|
 |
|
Viewing report
|
|
|
|
CNS Drug Discoveries: Alzheimer's Disease Chapter
Espicom Business Intelligence Ltd, Aug 2008, Pages: 62
This chapter of CNS Drug Discoveries focuses on the Alzheimer’s disease market.
By 2014, there will be considerable change in the Alzheimer’s disease (AD) market due to generic competition, better utilisation of acetylcholinesterase inhibitors and new product launches which, for the first time, will treat the condition and not the symptoms.
AD affects approximately 19 million people worldwide, with a prevalence of approximately 1 per cent in the total population, although the risk of being afflicted with AD increases with age.
In 2007, approximately US$5.5 billion was spent on the symptomatic treatment of AD. The vast majority of this revenue was generated by just four drugs within two main classes, the acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists. However, since all four brands face patent expiration within the next four to five years, this will have a considerable impact on the revenues of the companies involved.
Since all currently-available treatments are symptomatic treatments, aimed at alleviating the symptoms of the disease and trying to slow the deterioration of the patients, there is a significant unmet need for improved drugs that can modify the underlying course of the disease.
There is considerable research being undertaken in this area, although there have been many casualties including Bellus Health's Alzhemed (tramiprosate), Axonyx' phenserine and sanofi-aventis' xaliproden (all discontinued from Phase III trials), and most recently, the lack of efficacy demonstrated by Myriad Genetics/Lundbeck's Flurizan (tarenflurbil). The current front runner is Wyeth/Elan's bapineuzumab, although this too is facing challenges in development. It may be some time before the first disease-modifying agents emerge which could revolutionise the way AD is treated.
Key AD questions answered include:
- By what % will the number of AD patients being treated in developed markets increase annually?
- How are approvals for new indications affecting the sales potential of Eisai/Pfizer’s Aricept?
- What are the characteristics and prospects for Wyeth/Elan’s bapineuzumab?
- What competition could arise for Forest/Lundbeck’s Namenda/Ebixa?
Also available
CNS Drug Discoveries: What the Future Holds 2008
Customers who bought this item also bought
CNS Drug Discoveries: Parkinson's Disease Chapter
Alzheimer Disease - New Drugs, Markets and Companies
Alzheimer's Disease Biomarkers, 2009
Emerging Drug Targets in Alzheimer's Disease
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
Thought Leader Insight & Analysis: Alzheimer's Disease
CNS Drug Discoveries: Neurodegenerative Disorders Chapter
CNS Drug Discoveries: Multiple Sclerosis Chapter
CNS Drug Discoveries: Schizophrenia Chapter
Alzheimer's Disease: Markets, Pipeline and Opportunities 2009
Drugs of Tomorrow: Alzheimer’s Disease - Ebixa Set to Expand Billion Dollar Market
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
|
|
|
|
